Ryan Mattison1, Richard A Larson. Show Affiliations » 1. Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL 60637, USA.
Abstract
Entities: Chemical Disease
Mesh： See more » Antineoplastic Agents/administration & dosageAntineoplastic Agents/therapeutic useBenzamidesDrug Administration ScheduleFollow-Up StudiesFusion Proteins, bcr-abl/geneticsGene Expression Regulation, LeukemicHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapyLeukemia, Myelogenous, Chronic, BCR-ABL Positive/geneticsLeukemia, Myelogenous, Chronic, BCR-ABL Positive/pathologyPiperazines/administration & dosagePiperazines/therapeutic usePyrimidines/administration & dosagePyrimidines/therapeutic useReverse Transcriptase Polymerase Chain ReactionTreatment Outcome
Substances： See more » Antineoplastic AgentsBenzamidesPiperazinesPyrimidinesImatinib MesylateFusion Proteins, bcr-abl
Year: 2009 PMID： 19455466 DOI： 10.1080/10428190902934951
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022